Zobrazeno 1 - 10
of 833
pro vyhledávání: '"Kenneth W Mahaffey"'
Autor:
Bernard Zinman, Bruce Neal, George L Bakris, Vlado Perkovic, Meg J Jardine, Kris Rogers, Jie Yu, Adeera Levin, Dick de Zeeuw, Hong Zhang, Kenneth W Mahaffey, Clare Arnott, Rajiv Agarwal, Gian Luca Di Tanna, Carol Pollock, David C Wheeler, Christopher P Cannon, David M Charytan, Hiddo J Lambers Heerspink, Norman Rosenthal
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 11, Iss 3 (2023)
Introduction Relationships between glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and impact on kidney and cardiovascular outcomes are uncertain.Research design and methods We analyzed 4395 individuals with prebaseline and po
Externí odkaz:
https://doaj.org/article/83663dfd99b5429482efb801e4aa82d8
Publikováno v:
Journal of Clinical and Translational Science, Vol 4, Pp 60-60 (2020)
OBJECTIVES/GOALS: The Stanford CTSA Program has started to create Clinical Research Units (CRUs) with the goal to establish CRUs in all clinical departments by the end of 2020. CRUs will be responsible for managing the portfolio of projects proposed
Externí odkaz:
https://doaj.org/article/0c4c327327304bf4bc60d7dd682df6e4
Autor:
Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo. J. L. Heerspink
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided by multivariable pre
Externí odkaz:
https://doaj.org/article/9ab201997da946b29c0687e277525199
Autor:
Ashish Sarraju, Clark Seninger, Vijaya Parameswaran, Christina Petlura, Tamara Bazouzi, Kiranbir Josan, Upinder Grewal, Thomas Viethen, Hardi Mundl, Joachim Luithle, Leonard Basobas, Alexis Touros, Michael J. T. Senior, Koen De Lombaert, Kenneth W. Mahaffey, Mintu P. Turakhia, Rajesh Dash
Publikováno v:
npj Digital Medicine, Vol 5, Iss 1, Pp 1-7 (2022)
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic curtailed clinical trial activity. Decentralized clinical trials (DCTs) can expand trial access and reduce exposure risk but their feasibility remains uncertain. We evaluated DCT feasibility f
Externí odkaz:
https://doaj.org/article/984329d31e27451a98b54ad847696b8f
Autor:
Jing‐Wei Li, Clare Arnott, Hiddo J. L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler, David M. Charytan, Jennifer Barraclough, Gemma A. Figtree, Rajiv Agarwal, George Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Meg J. Jardine
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 16 (2022)
Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In
Externí odkaz:
https://doaj.org/article/46cbfff7ef724eea8154c25524ea230a
Autor:
Francis E. Ugowe, MD, Anne S. Hellkamp, MS, Allen Wang, BS, Richard C. Becker, MD, Scott D. Berkowitz, MD, Günter Breithardt, MD, Keith A.A. Fox, MB ChB, Jonathan L. Halperin, MD, Graeme J. Hankey, MD, Kenneth W. Mahaffey, MD, Christopher C. Nessel, MD, Daniel E. Singer, MD, Manesh R. Patel, MD, Jonathan P. Piccini, MD, MHS, FHRS
Publikováno v:
Heart Rhythm O2, Vol 2, Iss 3, Pp 215-222 (2021)
Background: Insulin use may be a better predictor of stroke risk and morbidity and mortality than diabetes in patients with atrial fibrillation (AF). Objectives: Determine if the increased risk of stroke observed in patients with AF and diabetes is r
Externí odkaz:
https://doaj.org/article/6a0db23014864b818546be226fa651ca
Autor:
Jie Yu, Clare Arnott, Brendon L. Neuen, Hiddo L. Heersprink, Kenneth W. Mahaffey, Christopher P. Cannon, Sadiya S. Khan, Abigail S. Baldridge, Sanjiv J. Shah, Yuli Huang, Chao Li, Gemma A. Figtree, Vlado Perkovic, Meg J. Jardine, Bruce Neal, Mark D. Huffman
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 1482-1493 (2021)
Abstract Aims The CANVAS Program identified the effect of canagliflozin on major adverse cardiovascular events (MACE) differed according to whether participants were using diuretics at study commencement. We sought to further evaluate this finding re
Externí odkaz:
https://doaj.org/article/851c1009f53f4b14acb1ca781b58c180
Autor:
Christoph B. Olivier, MD, Stephanie K. Middleton, BS, Natasha Purington, MS, Sumana Shashidhar, MS, Jody Hereford, BSN, MS, Kenneth W. Mahaffey, MD, Mintu P. Turakhia, MD, MAS, FHRS
Publikováno v:
Cardiovascular Digital Health Journal, Vol 2, Iss 2, Pp 101-108 (2021)
Background: We performed a trial to evaluate the efficacy of a blended intervention with personalized health coaching and virtual cardiac rehabilitation to improve medication adherence and risk factors. The trial was terminated early. Here, we descri
Externí odkaz:
https://doaj.org/article/64e7bf8a4b2f41339dda5259bbe0e464
Autor:
Michael Szarek, Connie Hess, Manesh R. Patel, W. Schuyler Jones, Jeffrey S. Berger, Iris Baumgartner, Brian Katona, Kenneth W. Mahaffey, Lars Norgren, Juuso Blomster, Frank W. Rockhold, Judith Hsia, F. Gerry R. Fowkes, Marc P. Bonaca
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 11 (2022)
Background Peripheral artery disease (PAD) is associated with heightened risk for major adverse cardiovascular and limb events, but data on the burden of risk for total (first and potentially subsequent) events, and the association with polyvascular
Externí odkaz:
https://doaj.org/article/18699052c2634fccb3f16e04b1efee27
Publikováno v:
Cardiology and Therapy, Vol 9, Iss 2, Pp 219-225 (2020)
Abstract In 2013, canagliflozin was the first sodium–glucose cotransporter 2 inhibitor (SGLT2i) approved by the US Food and Drug Administration for the treatment of type 2 diabetes (T2DM). Today, there are four SGLT2i approved for T2DM, and some SG
Externí odkaz:
https://doaj.org/article/f061f5b9f3984811b39d766582466b0f